July 10, 2026 / US GLP-1 access and pricing data — a real-time index of brand-name GLP-1 (Ozempic, Wegovy, Zepbound, Mounjaro) stock, dose availability, and cash-pay price across pharmacies and manufacturer direct channels.

GLP-1 pharmacy index

Retail & Local high difficulty Free consumer finder for top-of-funnel and crowdsourced data; revenue from a B2B availability/price API and dashboard licensed to telehealth prescribers, employers/benefits brokers, and PBMs, plus possible referral fees to legitimate pharmacy or manufacturer-direct channels (no clinical affiliate of the drug itself). healthtech glp-1 pharmacy-data price-transparency b2b-data telehealth

Build This Idea Audience Intelligence Execution Scorecard Build decision memo Download decision dossier (PDF) Download research bundle Markdown JSON

Building this? Claim it

Verdict Research · 51/100

This week's test

Within 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments: a 'find my dose cheapest near me' consumer page, and a B2B page pitching the normalized availability/price API to telehealth and employer-benefits teams. Validate if at least 200 consumer stock reports are submitted in one metro and at least two B2B prospects sign a paid pilot or LOI for the feed.

Run the 7-day sprint ↓

Kill it if

Fewer than five qualified buyers agree to discuss the workflow after targeted outreach.

All kill criteria ↓

Reader demand signal

Would you build this? Would you pay?

One tap each — anonymous, one vote per question per day. Tallies update as readers weigh in.

Would you build this?

Be the first to weigh in

Would you pay for this?

Be the first to weigh in

Visual opportunity dashboard

Read the idea like a product signal board.

These visuals are generated from the report's existing scores. They make the decision path scannable without pretending to be live market data.

Signal model

GLP-1 pharmacy index

Validation 51/100 Research

Confidence 55% Editorial confidence

Score avg 6/10 Scorecard average

Proof 6.3/10 Proof signal average

Score radar

Decision balance

Value equation

Offer strength

Dream outcome 8/10

Perceived likelihood 6/10

Time delay 4/10

Effort and sacrifice 4/10

Market map

Category king candidate

Uniqueness Customer value

High value plus high uniqueness deserves deeper research; lower uniqueness requires a clear distribution advantage.

Validation funnel

From pain to product.

Buyer pain Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus...

5.7/10

Concierge proof Within 60 days, build a single-metro crowdsourced stock + cash-price tracker for...

6.3/10

Paid wedge Concierge review or paid template

6/10

Repeatable product Free consumer finder for top-of-funnel and crowdsourced data; revenue from a B2B...

6.2/10

Evidence heatmap

Signal intensity.

Why now 5/10 Demand visibility

Why now 4/10 Tooling readiness

Why now 4/10 Budget clarity

Why now 8/10 Competitive window

Pain 5/10 Repeated workflow friction

Money 4/10 Budget hypothesis

Urgency 6/10 Switching pressure

Distribution 10/10 Reachable buyer language

Lifecycle timing

Validation window (58/100): enough signal exists to run the sprint, but the market has not clearly heated yet.

Deterministic stage assignment from re-check status, demand signals, complaint echo, and competitive saturation.

58/100

Validating

Adoption substrate is up 760.1% across matched packages.

No funded competitor penalty is currently applied.

Demand

67/100

Not old enough for a 30-day re-check yet.

Saturation

24/100

0 funded signals across 3 matched competitor signals.

Complaint echo

22/100

Matched adoption substrate is up 760.1%.

Validation engine

Evidence-backed idea-validation score.

The score uses a versioned 2026 rubric across demand, problem severity, willingness to pay, competitive saturation, and feasibility.

51/100

Research

Research is the current validation verdict: problem severity is the strongest signal, while competitive saturation is the main evidence gap to close before scaling the build.

Rubric version: INAV-VALIDATION-2026-06-04 / generated July 10, 2026

Demand signal

24% weight

5.9/10

Demand looks thin because the report has 4 source-backed signal(s), an editorial confidence of 55/100, and a defined buyer in US GLP-1 access and pricing data — a real-time index of brand-name GLP-1 (Ozempic, Wegovy, Zepbound, Mounjaro) stock, dose availability, and cash-pay price across pharmacies and manufacturer direct channels..

FDA removed tirzepatide (Mounjaro/Zepbound) from its shortage list in December 2024 and semaglutide (Ozempic/Wegovy) in February 2025, with phased 503A/503B compounding cutoff deadlines in early-to-mid 2025 — shifting the problem from blanket shortage to localized, dose-level stockouts.
Target buyer: Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed.

Problem severity

22% weight

6.3/10

Problem severity is thin when the buyer pain, customer value, and dream-outcome scores are combined.

Even after the FDA declared the GLP-1 shortages resolved (tirzepatide Dec 2024, semaglutide Feb 2025), patients still hit localized stockouts of specific doses and face cash prices that swing from roughly $199 to $1,000+ per month depending on whether they buy via LillyDirect, NovoCare, Costco, Walmart, or a retail pharmacy. There is no neutral, normalized, machine-readable index that tracks dose-level availability and the cheapest legitimate price for a given drug, dose, and ZIP at a point in time.
FDA removed tirzepatide (Mounjaro/Zepbound) from its shortage list in December 2024 and semaglutide (Ozempic/Wegovy) in February 2025, with phased 503A/503B compounding cutoff deadlines in early-to-mid 2025 — shifting the problem from blanket shortage to localized, dose-level stockouts.

Willingness to pay

20% weight

5/10

Willingness to pay is weak; the model has a monetization hypothesis, but it must still be proven through paid pilots or explicit pricing objections.

Free consumer finder for top-of-funnel and crowdsourced data; revenue from a B2B availability/price API and dashboard licensed to telehealth prescribers, employers/benefits brokers, and PBMs, plus possible referral fees to legitimate pharmacy or manufacturer-direct channels (no clinical affiliate of the drug itself).
Within 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments: a 'find my dose cheapest near me' consumer page, and a B2B page pitching the normalized availability/price API to telehealth and employer-benefits teams. Validate if at least 200 consumer stock reports are submitted in one metro and at least two B2B prospects sign a paid pilot or LOI for the feed.

Competitive saturation

18% weight

3.9/10

Competitive room is reduced by 3 recorded alternative(s); the wedge must stay narrow and differentiated.

Recorded alternative: Ro GLP-1 Supply Tracker
Competitive score rewards a narrow wedge, not absence of research.

Feasibility

16% weight

4/10

Feasibility is weak for a high build if the MVP is limited to the first measurable workflow.

Within 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments: a 'find my dose cheapest near me' consumer page, and a B2B page pitching the normalized availability/price API to telehealth and employer-benefits teams. Validate if at least 200 consumer stock reports are submitted in one metro and at least two B2B prospects sign a paid pilot or LOI for the feed.
Pharmacy stock data is not openly published — chains like CVS and Walgreens expose availability only in their own apps, so the index must rely on crowdsourced and scraped signals that can be stale, incomplete, or blocked by terms of service.

Next validation step

Validation sprint

Seven days to a build / kill decision.

Derived from this report's own validation test, channels, offers, and kill criteria. Each day has a threshold, so the week ends in a decision instead of a feeling.

Day 1

Build the buyer list

List 50-100 named two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying b2b buyers — telehealth prescribers, employer benefits teams, and pbms/brokers who license the availability and price feed. prospects from Community pain posts and Direct outreach — names, not categories.

Threshold: 50+ named, reachable buyers on the list.

Day 2

Join the watering holes

Join and observe Reddit / forums, Launch communities, Review and alternative pages. Collect the exact words buyers use for this pain.

Threshold: 10+ verbatim pain quotes captured.

Day 3

Send first outreach

Send the cold outreach template (below) to 15 buyers from the day-1 list, personalized with one detail each.

Threshold: 15 sent; 3+ replies of any kind.

Day 4

Run buyer interviews

Hold 15-minute calls using the interview script (below). Listen for current workarounds and what they cost.

Threshold: 3+ completed interviews.

Day 5

Run the report's validation test

Within 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments:...

Threshold: Problem resonance: 5+ calls or 10+ detailed replies.

Day 6

Make the smoke offer

Offer "Concierge review or paid template" at $19-$99 to every interviewed buyer. Manual delivery is fine — payment is the signal.

Threshold: 1+ pre-commitment (payment, signed LOI, or scheduled paid pilot).

Day 7

Decide against the kill criteria

Score the week against this report's kill criteria, then take the stated next validation step: Within 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments:...

Threshold: A written build / keep-testing / kill decision.

Pass signal

Pass: thresholds on days 3, 4, and 6 are met — proceed to the next validation step with real buyer language in hand.

Fail signal

Kill or rethink if the week confirms: Fewer than five qualified buyers agree to discuss the workflow after targeted outreach.

Open sprint tracker

Research workflow

Decision scorecard.

The report is structured to force a yes, no, or test decision instead of leaving the reader with a loose brainstorm.

Opportunity

Promising

6/10

GLP-1 pharmacy index has an editorial confidence score of 55/100 before live buyer validation.

Problem

Promising

5/10

Feasibility

Needs proof

4/10

A high build can work if the MVP stays limited to the first repeated workflow.

Why now

Exceptional

9/10

The market just shifted from a shortage problem to a fragmentation problem: brand GLP-1s came off the FDA shortage list in 2024-2025, compounding deadlines forced compounders out, and manufacturers simultaneously launched competing direct cash-pay channels (LillyDirect, NovoCare, plus Costco/Walmart and the TrumpRx portal in Feb 2026). That created a sprawl of prices and dose-level supply gaps that no single source normalizes, exactly when employers report GLP-1s are roughly 20% of pharmacy spend and need cost-steering data.

Market and money

Business fit and offer ladder.

Revenue potential

$250K-$2M ARR potential if the wedge proves budget urgency and becomes a recurring workflow.

Execution difficulty

Execution is high; the main constraint is staying narrow enough for a first proof loop.

Go-to-market

Start with manual concierge output, direct outreach, and community proof before paid acquisition.

Founder fit

Best for an AI-assisted solo founder who can interview the buyer and ship a focused first version quickly.

1. Lead magnet

Glp-1 Pharmacy Index checklist

Free

Helps Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed. audit the painful workflow before buying software.

Capture qualified leads and learn the buyer's exact language.

2. Frontend offer

Concierge review or paid template

$19-$99

Delivers the first useful output manually before automation is trusted.

Validate urgency, workflow fit, and willingness to pay.

3. Core offer

GLP-1 pharmacy index focused SaaS

$49-$499/month

Turns the recurring manual workflow into a repeatable product loop.

Create the recurring revenue product after the narrow wedge survives tests.

4. Continuity

Monitoring, benchmarks, and monthly reporting

$99-$1,000/year add-on

Keeps the buyer engaged with ongoing proof, saved time, or reduced risk.

Increase retention and make the product part of a routine.

5. Backend offer

Done-with-you setup, agency, or team rollout

Custom

Adds implementation help, integrations, and workflow migration.

Capture higher-value accounts once the productized wedge is proven.

Economics

Price-anchored revenue scenarios.

Derived from this report's "Core offer" offer-ladder stage ($49-$499/month). These are price-anchored scenarios, not market-size claims.

Proof

10 customers

$490-$4,990 MRR

Ten paying customers proves willingness to pay and funds continued validation.

Wedge

50 customers

$2,450-$24,950 MRR

Fifty customers in one niche makes the workflow the default in that circle and feeds referrals.

Vertical leader

250 customers

$12,250-$124,750 MRR

A few hundred accounts in one vertical is a real business before any horizontal expansion.

Break-even

At $49-$499/month, 1 customers cover the stated Local-first MVP budget: $0-$10K before paid acquisition. budget within a month; fewer if they land at the top of the range.

Sizing the buyer universe

Size the buyer universe in one day: count two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying b2b buyers — telehealth prescribers, employer benefits teams, and pbms/brokers who license the availability and price feed. reachable through the report's channels (directories, associations, communities) until the list stops growing — the test only needs the first 100 names, not a TAM estimate.

Pricing benchmark

3 adjacent products recorded (2 strong). Position the price against what two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying b2b buyers — telehealth prescribers, employer benefits teams, and pbms/brokers who license the availability and price feed. already pays in time or tooling, and verify each named alternative's public pricing during the sprint.

Evidence

Why now and proof signals.

Why now

Demand visibility

5/10

FDA removed tirzepatide (Mounjaro/Zepbound) from its shortage list in December 2024 and semaglutide (Ozempic/Wegovy) in February 2025, with phased 503A/503B compounding cutoff deadlines in early-to-mid 2025 — shifting the problem from blanket shortage to localized, dose-level stockouts.

Build only if the complaint repeats across interviews, posts, or existing workflow artifacts.

Tooling readiness

4/10

AI-assisted product work and managed infrastructure reduce the first-version cost.

The first release should automate one high-friction step rather than become a broad platform.

Budget clarity

4/10

Free consumer finder for top-of-funnel and crowdsourced data; revenue from a B2B availability/price API and dashboard licensed to telehealth prescribers, employers/benefits brokers, and PBMs, plus possible referral fees to legitimate pharmacy or manufacturer-direct channels (no clinical affiliate of the drug itself).

Ask for money during validation before building the full workflow.

Competitive window

8/10

The wedge is specific enough to test without claiming the whole market.

Position around one buyer and one measurable first-win outcome.

Proof signals

Pain: Repeated workflow friction

5/10

Money: Budget hypothesis

4/10

Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed. is the first group to test because the monetization path is: Free consumer finder for top-of-funnel and crowdsourced data; revenue from a B2B availability/price API and dashboard licensed to telehealth prescribers, employers/benefits brokers, and PBMs, plus possible referral fees to legitimate pharmacy or manufacturer-direct channels (no clinical affiliate of the drug itself).

Urgency: Switching pressure

6/10

Urgency becomes real only if the current workaround costs time, risk, money, or reputation every week.

Distribution: Reachable buyer language

10/10

The first channel should be whichever source lane already contains the buyer's vocabulary.

Positioning

Market gaps and execution plan.

Underserved segments

Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed. who still run the workflow in spreadsheets, generic docs, email, or chat threads.
Small teams in US GLP-1 access and pricing data — a real-time index of brand-name GLP-1 (Ozempic, Wegovy, Zepbound, Mounjaro) stock, dose availability, and cash-pay price across pharmacies and manufacturer direct channels. that feel the pain weekly but are too narrow for broad incumbents.
New adopters who need guided proof before committing to a larger platform.

Feature gaps

A narrow workflow that reaches value without configuration-heavy onboarding.
A buyer-facing proof artifact that shows time saved, risk reduced, or communication improved.
A handoff path from manual concierge service to repeatable software.

Differentiation levers

Use specificity as the wedge: one buyer, one workflow, one measurable result.
Show proof earlier than broad competitors with before-and-after examples and small pilot data.
Keep implementation lighter than incumbent suites or generic AI assistants.

Execution snapshot

Type: Two-sided marketplace
Timeline: 8-12 weeks
Budget: Local-first MVP budget: $0-$10K before paid acquisition.
Initial offer: Concierge review or paid template

Build only the first-win workflow for "GLP-1 pharmacy index" and keep research, setup, and exceptions manual until the wedge is proven.

Community pain posts

Weekly

Use communities and forums where Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed. already describe the painful workflow.

Problem teardown, interview ask, and short demo clip / 5 qualified calls or 10 detailed replies in 7 days

Direct outreach

Daily during validation

Direct conversations are the fastest way to verify budget ownership and switching cost.

Concierge pilot offer with a manually prepared sample / 3 paid pilots, LOIs, or budget-owner follow-ups

Searchable comparison content

Bi-weekly

Alternative and comparison pages reveal objections, pricing language, and buying intent.

Before-and-after page or alternatives memo for the exact workflow / Organic clicks, booked demos, or waitlist joins from comparison intent

Launch directory

Once MVP is clickable

Launches test whether the promise is legible to people outside the first interview set.

Single-purpose demo and first-win story / 25% demo completion or 10 waitlist joins

Competitive Landscape

Alternatives, incumbents, and whitespace.

This section names likely workarounds and public players so the report can argue where the wedge is still open.

GLP-1 pharmacy index should be positioned against generic AI assistants, no-code workarounds, and any vertical incumbent that already owns US GLP-1 access and pricing data — a real-time index of brand-name GLP-1 (Ozempic, Wegovy, Zepbound, Mounjaro) stock, dose availability, and cash-pay price across pharmacies and manufacturer direct channels.. The opening is a narrower first-win workflow for Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed..

direct

Ro GLP-1 Supply Tracker

competitor product

A free, open-access tool from a well-funded telehealth company that does almost exactly the consumer side of this idea — crowdsourced plus FDA-sourced dose-level GLP-1 availability with location alerts — used as a top-of-funnel acquisition channel, so it is a direct incumbent. direct

Medfinder

competitor product

A paid concierge medication-finding service that locates GLP-1 and other hard-to-find drugs in stock near a patient, including insurance matching, competing directly on the 'find it in stock' value proposition with a revenue model already in place. adjacent

GoodRx GLP-1 cost and savings guide

competitor product

GoodRx already aggregates and compares pharmacy-level GLP-1 cash prices and savings, overlapping with the price-index side of this idea and positioning it as a potential entrant or partner on price transparency, though it does not yet provide real-time dose-level stock availability. workaround

Notion

Workspace and documentation

Competes when buyers can solve the pain with templates, checklists, and shared pages. workaround

Airtable

No-code database

Competes when the first version can be modeled as a lightweight database and workflow view. workaround

Asana

Project management

Competes where the buyer can express the workflow as tasks, owners, and due dates.

Whitespace

A narrow workflow that reaches value without configuration-heavy onboarding.
A buyer-facing proof artifact that shows time saved, risk reduced, or communication improved.
A handoff path from manual concierge service to repeatable software.
Use specificity as the wedge: one buyer, one workflow, one measurable result.
Show proof earlier than broad competitors with before-and-after examples and small pilot data.
Keep implementation lighter than incumbent suites or generic AI assistants.
Own the specific buyer workflow instead of selling a broad AI assistant.

Positioning moves

Lead with the exact buyer: Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed..
Show a proof artifact for: Within 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments: a 'find my dose cheapest near me' consumer page, and a B2B page pitching the normalized availability/price API to telehealth and employer-benefits teams. Validate if at least 200 consumer stock reports are submitted in one metro and at least two B2B prospects sign a paid pilot or LOI for the feed.
Name the generic-assistant workaround directly and explain what it misses.
Offer concierge setup before promising a full platform.

Public source Ro.co https://ro.co/weight-loss/supply-tracker/ Public source Medfinder https://www.medfinder.com/ Public source GoodRx https://www.goodrx.com/classes/glp-1-agonists/glp-1-drugs-cost-and-savings Public source Notion https://www.notion.com/ Public source Airtable https://www.airtable.com/ Public source Asana https://asana.com/ Public source Report source https://www.drugtopics.com/view/glp-1-no-longer-on-fda-s-drug-shortage-list Public source Report source https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize

Audience Companion

Segments, channels, and intent language.

The companion is also published as a standalone HTML page and Markdown file for research handoff.

Primary audience

Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed. is the first audience because the report already names a repeated pain, reachable channels, and a validation test that can be run before software is complete.

pharmacy workflowindex validationpharmacy aiindex automationhealthtechglp-1pharmacy-dataprice-transparency

First validation channels

Reddit / forums: Post a problem teardown for US GLP-1 access and pricing data — a real-time index of brand-name GLP-1 (Ozempic, Wegovy, Zepbound, Mounjaro) stock, dose availability, and cash-pay price across pharmacies and manufacturer direct channels. and ask how people solve it today.
Launch communities: Ship a narrow demo and watch which promise gets clicks.
Review and alternative pages: Write an alternatives page that owns one narrow use case.
Community pain posts: Problem teardown, interview ask, and short demo clip

Open audience intelligence Download Markdown

Time To Execute

Execution-readiness scorecard.

The score turns the report into bottlenecks, accelerators, and a dated first-month launch plan.

43/100

Research first

GLP-1 pharmacy index scores 43/100 for execution readiness. The recommended next step is Within 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments: a 'find my dose cheapest near me' consumer page, and a B2B page pitching the normalized availability/price API to telehealth and employer-benefits teams. Validate if at least 200 consumer stock reports are submitted in one metro and at least two B2B prospects sign a paid pilot or LOI for the feed.

Execution scorecard is generated from report validation, confidence, feasibility, founder fit, and difficulty.

Bottlenecks

Pharmacy stock data is not openly published — chains like CVS and Walgreens expose availability only in their own apps, so the index must rely on crowdsourced and scraped signals that can be stale, incomplete, or blocked by terms of service.
Regulatory and liability exposure: showing or routing to GLP-1 sources touches HIPAA, state pharmacy law, drug-advertising rules, and the post-shortage crackdown on compounded GLP-1s — surfacing illegitimate or compounded sources could create legal risk.
Incumbents already occupy the niche: Ro (a well-funded telehealth company) offers a free supply tracker as a funnel, and Medfinder offers a paid concierge stock-finding service, so a standalone index must out-execute on data freshness and the B2B feed.
Demand is shortage-driven and could soften further as supply fully normalizes and GLP-1 pills arrive, compressing the consumer pain point and the window for the data business.
A broad AI assistant can flatten differentiation unless the wedge is painfully specific.

First milestones

2026-07-11: Frame the wedge
2026-07-14: Interview 10 people who match the buyer persona.
2026-07-18: Ship a clickable demo or concierge workflow that produces the first useful artifact.
2026-07-25: Run one paid pilot or collect explicit pricing objections before automating the rest.

Open execution scorecard Generate dated plan Download Markdown

Frameworks

Value equation, matrix, and ACP.

Open the framework detail (value equation, market matrix, ACP)

Value equation

Dream outcome: 8/10
Perceived likelihood: 6/10
Time delay: 4/10
Effort and sacrifice: 4/10

Category king candidate

High value plus high uniqueness deserves deeper research; lower uniqueness requires a clear distribution advantage.

Audience / Community / Product

Audience: 5/10
Community: 9/10
Product: 4/10

Trend and keyword signals are directional until verified with live customers and source citations.

Founder lens

Fit, roast, and kill criteria.

6/10

Founder fit

A solo or AI-assisted founder with direct access to Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed..

Advantages

Can talk to the buyer before writing much code.
Can ship a narrow first-win demo quickly.
Can use local-first research artifacts to keep validation moving without a large team.

Gaps

Needs real buyer access, not only desk research.
Needs proof of budget or repeated urgency.
Needs a crisp wedge before broad product work starts.

Roast

Promising enough to test, not strong enough to build broadly.

Blind spots

Pharmacy stock data is not openly published — chains like CVS and Walgreens expose availability only in their own apps, so the index must rely on crowdsourced and scraped signals that can be stale, incomplete, or blocked by terms of service.
A broad AI assistant can flatten differentiation unless the wedge is painfully specific.
The first release can become a generic dashboard if the job is not named tightly.

Hard questions

Who wakes up already trying to solve this?
What do they stop paying for or stop doing when this works?
What proof would make a skeptical buyer trust it in one screen?
What is the smallest paid version of this idea?

Kill criteria

Fewer than five qualified buyers agree to discuss the workflow after targeted outreach.
No buyer can name a current cost in time, money, risk, or reputation.
The first demo does not produce a clear next step, paid pilot, or specific objection.

Next actions

Write the one-sentence promise and test it in the strongest channel.
Create the lead magnet and use it to recruit interviews.
Build the smallest demo that proves the first win.

Action suite

Move from reading to testing.

Local-first handoff cards copy prompts or structured data without requiring an account.

Build This Idea

Copy the focused build brief for a coding agent.

Roast

Copy the critique lens and blind spots before committing time.

Landing Page

Copy a landing-page brief based on buyer, pain, and validation.

Brand Package

Copy positioning inputs for naming, messaging, and design direction.

Ad Creatives

Copy campaign angles for buyer-problem validation.

Export Data

Copy structured JSON for a research engine, roadmap tracker, or another agent.

Founder Fit

Copy the founder-fit self-check before entering build mode.

First contact kit

Outreach template and interview script.

Built from this report's buyer, pain language, and channels. Personalize one detail per message — these are starting points, not spam ammunition.

Cold outreach message

Question about pharmacy workflowHow are you handling even after the fda declared the glp-1 shortages resolved (t...15 minutes on a us glp-1 access and pricing data — a real-time index of brand-name glp-1 (ozempic, wegovy, zepbound, mounjaro) stock, dose availability, and cash-pay price across pharmacies and manufacturer direct channels. workflow?

Hi {{firstName}},

I'm researching how two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying b2b buyers — telehealth prescribers, employer benefits teams, and pbms/brokers who license the availability and price feed. handle this today: Even after the FDA declared the GLP-1 shortages resolved (tirzepatide Dec 2024, semaglutide Feb 2025), patients still hit localized stockou...

I'm not selling anything yet — I'm testing whether "GLP-1 pharmacy index" is worth building, and I'd rather learn from people living the workflow than guess.

Would you trade 15 minutes for first access (and a say in what gets built) if it goes ahead?

{{yourName}}

Buyer interview script

Walk me through the last time this happened: Even after the FDA declared the GLP-1 shortages resolved (tirzepatide Dec 2024, semaglutide Feb 2025), patients still h... What did you actually do?
What does that workaround cost you — in hours, money, or risk — in a normal month?
What have you already tried or bought to fix it, and why didn't it stick?
If "Launch a free consumer 'find-it-in-stock and cheapest cash price' web tool for the four brand GLP-1..." existed, what would have to be true for you to switch in the first week?
Who else feels this worse than you do — and would you introduce me?

Where to send it

Community pain posts — Problem teardown, interview ask, and short demo clip
Direct outreach — Concierge pilot offer with a manually prepared sample
Searchable comparison content — Before-and-after page or alternatives memo for the exact workflow
Reddit / forums — Post a problem teardown for US GLP-1 access and pricing data — a real-time index of brand-name GLP-1 (Ozempic, Wegovy, Zepbound, Mounjaro) stock, dose availability, and cash-pay price across pharmacies and manufacturer direct channels. and ask how people solve it today.
Launch communities — Ship a narrow demo and watch which promise gets clicks.

Handoff

Build and review prompts.

Build prompt

Build a narrow MVP for "GLP-1 pharmacy index" for Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed.. Preserve the evidence, build only the first-win workflow, include source links, and treat Within 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments: a 'find my dose cheapest near me' consumer page, and a B2B page pitching the normalized availability/price API to telehealth and employer-benefits teams. Validate if at least 200 consumer stock reports are submitted in one metro and at least two B2B prospects sign a paid pilot or LOI for the feed. as the first acceptance gate.

Review prompt

Review the "GLP-1 pharmacy index" MVP for over-breadth, unsupported claims, weak buyer proof, privacy risk, and missing validation instrumentation. Do not approve expansion until the kill criteria and success metrics are measurable.

trade media / drugtopics.com GLP-1 No Longer on FDA's Drug Shortage List Reports that injectable tirzepatide (Mounjaro/Zepbound) came off the FDA shortage list in December 2024 and semaglutide (Ozempic/Wegovy) in February 2025, marking the shift from a national shortage to residual, localized supply issues. business media / cnbc.com Telehealth company Ro launches GLP-1 supply tracker to help patients navigate shortages Describes Ro's free, open-access GLP-1 Supply Tracker that combines crowdsourced patient reports with the FDA shortage list and alerts users when a needed drug and dose is found within 100 miles, demonstrating real consumer demand for dose-level availability data. business media / cnbc.com Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site Details manufacturer cash-pay price cuts on LillyDirect for Zepbound vials and the broader self-pay GLP-1 pricing war with Novo Nordisk's NovoCare, evidencing the wide, channel-dependent price variation a price index would normalize. industry research / shrm.org How Much of Employers' Annual Claims Do GLP-1 Drugs Account For? SHRM analysis showing GLP-1 drugs now represent roughly 20% of total prescription drug costs and about 10.5% of total annual employer pharmacy claims in 2025, establishing the B2B buyer's cost pressure and willingness to pay for steering data.

Pivot map

If this exact wedge isn't yours, these are adjacent.

Derived deterministically from this report's buyers, vertical language, and business model.

Same problem, different buyer: Budget owner who feels the operational cost of the broken workflow.

The workflow pain in this report is not exclusive to two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying b2b buyers — telehealth prescribers, employer benefits teams, and pbms/brokers who license the availability and price feed.. Budget owner who feels the operational cost of the broken workflow. faces the same friction with their own budget and urgency.

First test: Re-run day 3 of the sprint (15 outreach messages) against this buyer only, and compare reply rates before changing anything else.

Same workflow, adjacent vertical: pick the nearest regulated niche

No second vertical matched this report's language strongly, which usually means the wedge is horizontal. Horizontal wedges win by going vertical first.

First test: Pick the vertical where the pain costs the most per incident and rewrite the promise in its vocabulary.

Same wedge, alternate model: a data or monitoring product (alerts, benchmarks, watchlists)

This report monetizes via "Free consumer finder for top-of-funnel and crowdsourced data; revenue from a B2B availability/price API and dashboard licensed to telehealth prescribers, employers/benefits brokers, and PBMs, plus possible referral fees to legitimate pharmacy or manufacturer-direct channels (no clinical affiliate of the drug itself).". If buyers will not change their workflow, selling them awareness of the problem is the lower-friction wedge.

First test: Offer both versions on day 6 of the sprint and let the first pre-commitment choose the model.

Connections

Where this report sits in the intelligence graph.

Links from the ontology layer. Declared links are explicit in the research record; inferred links are keyword overlap and labeled as such. Full graph at /graph.json.

Evidence independence 88/100

7 source domains, 13 evidence edges. Dominant family: local:data/regulatory-clock.json. Audit all provenance.

In this vertical

Retail, E-commerce & Local Services

Ranked 6 of 6 by validation score among published Retail, E-commerce & Local Services reports.

Open the Retail & Local brief Intelligence dashboard

Validate · 69/100

Permit renewal calendar for mobile food vendors

Local services

Open report

Validate · 68/100

Operational SOP drift detector for franchise operators

Franchise operations

Open report

Validate · 66/100

Quote comparison brief for home renovation clients

Consumer services

Open report

Shared tags Retirement care planner Vertigo relief app

Full narrative

Read the full narrative report — the same research as prose (also in the Markdown export)

One-Line Verdict

GLP-1 pharmacy index should be tested as a narrow first-win workflow for Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed.. This is not a green light to build the full product. It is a structured prompt to test the buyer, the workflow, and the willingness to pay before committing engineering time.

Problem

Even after the FDA declared the GLP-1 shortages resolved (tirzepatide Dec 2024, semaglutide Feb 2025), patients still hit localized stockouts of specific doses and face cash prices that swing from roughly $199 to $1,000+ per month depending on whether they buy via LillyDirect, NovoCare, Costco, Walmart, or a retail pharmacy. There is no neutral, normalized, machine-readable index that tracks dose-level availability and the cheapest legitimate price for a given drug, dose, and ZIP at a point in time. The painful part is not merely information overload; it is the repeated translation from raw activity into an artifact someone can trust and act on. The first product should therefore focus on the artifact, not on becoming a broad research platform.

The initial hypothesis is that Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed. already has enough recurring friction to justify a narrow tool if it saves time, reduces risk, or improves communication in a visible way.

Who Pays

Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed. is the target buyer. The strongest early customer is the person who owns the consequence when this workflow is late, unclear, or inconsistent. They might pay when the product turns a recurring manual task into a dependable output with source links and a review path.

Evidence Signals

FDA removed tirzepatide (Mounjaro/Zepbound) from its shortage list in December 2024 and semaglutide (Ozempic/Wegovy) in February 2025, with phased 503A/503B compounding cutoff deadlines in early-to-mid 2025 — shifting the problem from blanket shortage to localized, dose-level stockouts.
Cash-pay prices for the same molecules vary widely by channel: LillyDirect lists Zepbound vials around $299-$449/month, NovoCare offers Wegovy near $349/month (with a $199 intro for two lowest doses), Costco and Walmart advertised $499/month cash options, while standard list prices run roughly $1,000-$1,500/month.
Telehealth company Ro launched a free, open-access GLP-1 Supply Tracker in May 2024 that combines crowdsourced reports with the FDA shortage list and alerts users when their drug/dose is found within 100 miles — proving real consumer demand for dose-level availability data.
Employer data shows GLP-1s now make up roughly 20% of total prescription drug costs and about 10.5% of total annual employer pharmacy claims in 2025, with total GLP-1 spend up about 50% year over year — a clear B2B willingness-to-pay signal for availability and price-steering data.

These signals are directional, not proof. The report should move to build only after live buyer conversations confirm that the workflow repeats and that the buyer can describe a concrete cost.

Scorecard

Opportunity: 6/10 (Promising) - GLP-1 pharmacy index has an editorial confidence score of 55/100 before live buyer validation.
Problem: 5/10 (Promising) - Even after the FDA declared the GLP-1 shortages resolved (tirzepatide Dec 2024, semaglutide Feb 2025), patients still hit localized stockouts of specific doses and face cash prices that swing from roughly $199 to $1,000+ per month depending on whether they buy via LillyDirect, NovoCare, Costco, Walmart, or a retail pharmacy. There is no neutral, normalized, machine-readable index that tracks dose-level availability and the cheapest legitimate price for a given drug, dose, and ZIP at a point in time.
Feasibility: 4/10 (Needs proof) - A high build can work if the MVP stays limited to the first repeated workflow.
Why now: 9/10 (Exceptional) - The market just shifted from a shortage problem to a fragmentation problem: brand GLP-1s came off the FDA shortage list in 2024-2025, compounding deadlines forced compounders out, and manufacturers simultaneously launched competing direct cash-pay channels (LillyDirect, NovoCare, plus Costco/Walmart and the TrumpRx portal in Feb 2026). That created a sprawl of prices and dose-level supply gaps that no single source normalizes, exactly when employers report GLP-1s are roughly 20% of pharmacy spend and need cost-steering data.

Validation Score

51/100 - Research. Research is the current validation verdict: problem severity is the strongest signal, while competitive saturation is the main evidence gap to close before scaling the build.

Rubric version: INAV-VALIDATION-2026-06-04

Demand signal: 5.9/10, weight 24%. Demand looks thin because the report has 4 source-backed signal(s), an editorial confidence of 55/100, and a defined buyer in US GLP-1 access and pricing data — a real-time index of brand-name GLP-1 (Ozempic, Wegovy, Zepbound, Mounjaro) stock, dose availability, and cash-pay price across pharmacies and manufacturer direct channels..
Problem severity: 6.3/10, weight 22%. Problem severity is thin when the buyer pain, customer value, and dream-outcome scores are combined.
Willingness to pay: 5/10, weight 20%. Willingness to pay is weak; the model has a monetization hypothesis, but it must still be proven through paid pilots or explicit pricing objections.
Competitive saturation: 3.9/10, weight 18%. Competitive room is reduced by 3 recorded alternative(s); the wedge must stay narrow and differentiated.
Feasibility: 4/10, weight 16%. Feasibility is weak for a high build if the MVP is limited to the first measurable workflow.

Next validation step: Within 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments: a ‘find my dose cheapest near me’ consumer page, and a B2B page pitching the normalized availability/price API to telehealth and employer-benefits teams. Validate if at least 200 consumer stock reports are submitted in one metro and at least two B2B prospects sign a paid pilot or LOI for the feed.

Business Fit

Revenue potential: $250K-$2M ARR potential if the wedge proves budget urgency and becomes a recurring workflow.
Execution difficulty: Execution is high; the main constraint is staying narrow enough for a first proof loop.
Go-to-market: Start with manual concierge output, direct outreach, and community proof before paid acquisition.
Founder fit: Best for an AI-assisted solo founder who can interview the buyer and ship a focused first version quickly.

Offer Ladder

Lead magnet: Glp-1 Pharmacy Index checklist (Free) - Helps Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed. audit the painful workflow before buying software. Goal: Capture qualified leads and learn the buyer’s exact language.
Frontend offer: Concierge review or paid template ($19-$99) - Delivers the first useful output manually before automation is trusted. Goal: Validate urgency, workflow fit, and willingness to pay.
Core offer: GLP-1 pharmacy index focused SaaS ($49-$499/month) - Turns the recurring manual workflow into a repeatable product loop. Goal: Create the recurring revenue product after the narrow wedge survives tests.
Continuity: Monitoring, benchmarks, and monthly reporting ($99-$1,000/year add-on) - Keeps the buyer engaged with ongoing proof, saved time, or reduced risk. Goal: Increase retention and make the product part of a routine.
Backend offer: Done-with-you setup, agency, or team rollout (Custom) - Adds implementation help, integrations, and workflow migration. Goal: Capture higher-value accounts once the productized wedge is proven.

Economics

Derived from this report’s “Core offer” offer-ladder stage ($49-$499/month). These are price-anchored scenarios, not market-size claims.

Proof (10 customers): $490-$4,990 MRR. Ten paying customers proves willingness to pay and funds continued validation.
Wedge (50 customers): $2,450-$24,950 MRR. Fifty customers in one niche makes the workflow the default in that circle and feeds referrals.
Vertical leader (250 customers): $12,250-$124,750 MRR. A few hundred accounts in one vertical is a real business before any horizontal expansion.
Break-even: At $49-$499/month, 1 customers cover the stated Local-first MVP budget: $0-$10K before paid acquisition. budget within a month; fewer if they land at the top of the range.
Sizing: Size the buyer universe in one day: count two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying b2b buyers — telehealth prescribers, employer benefits teams, and pbms/brokers who license the availability and price feed. reachable through the report’s channels (directories, associations, communities) until the list stops growing — the test only needs the first 100 names, not a TAM estimate.
Benchmark: 3 adjacent products recorded (2 strong). Position the price against what two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying b2b buyers — telehealth prescribers, employer benefits teams, and pbms/brokers who license the availability and price feed. already pays in time or tooling, and verify each named alternative’s public pricing during the sprint.

Why Now

Demand visibility: 5/10 - FDA removed tirzepatide (Mounjaro/Zepbound) from its shortage list in December 2024 and semaglutide (Ozempic/Wegovy) in February 2025, with phased 503A/503B compounding cutoff deadlines in early-to-mid 2025 — shifting the problem from blanket shortage to localized, dose-level stockouts. Build only if the complaint repeats across interviews, posts, or existing workflow artifacts.
Tooling readiness: 4/10 - AI-assisted product work and managed infrastructure reduce the first-version cost. The first release should automate one high-friction step rather than become a broad platform.
Budget clarity: 4/10 - Free consumer finder for top-of-funnel and crowdsourced data; revenue from a B2B availability/price API and dashboard licensed to telehealth prescribers, employers/benefits brokers, and PBMs, plus possible referral fees to legitimate pharmacy or manufacturer-direct channels (no clinical affiliate of the drug itself). Ask for money during validation before building the full workflow.
Competitive window: 8/10 - The wedge is specific enough to test without claiming the whole market. Position around one buyer and one measurable first-win outcome.

Proof Signals

Pain: 5/10 - Repeated workflow friction. FDA removed tirzepatide (Mounjaro/Zepbound) from its shortage list in December 2024 and semaglutide (Ozempic/Wegovy) in February 2025, with phased 503A/503B compounding cutoff deadlines in early-to-mid 2025 — shifting the problem from blanket shortage to localized, dose-level stockouts.
Money: 4/10 - Budget hypothesis. Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed. is the first group to test because the monetization path is: Free consumer finder for top-of-funnel and crowdsourced data; revenue from a B2B availability/price API and dashboard licensed to telehealth prescribers, employers/benefits brokers, and PBMs, plus possible referral fees to legitimate pharmacy or manufacturer-direct channels (no clinical affiliate of the drug itself).
Urgency: 6/10 - Switching pressure. Urgency becomes real only if the current workaround costs time, risk, money, or reputation every week.
Distribution: 10/10 - Reachable buyer language. The first channel should be whichever source lane already contains the buyer’s vocabulary.

Existing Product Check

strong: Ro GLP-1 Supply Tracker - A free, open-access tool from a well-funded telehealth company that does almost exactly the consumer side of this idea — crowdsourced plus FDA-sourced dose-level GLP-1 availability with location alerts — used as a top-of-funnel acquisition channel, so it is a direct incumbent.
strong: Medfinder - A paid concierge medication-finding service that locates GLP-1 and other hard-to-find drugs in stock near a patient, including insurance matching, competing directly on the ‘find it in stock’ value proposition with a revenue model already in place.
possible: GoodRx GLP-1 cost and savings guide - GoodRx already aggregates and compares pharmacy-level GLP-1 cash prices and savings, overlapping with the price-index side of this idea and positioning it as a potential entrant or partner on price transparency, though it does not yet provide real-time dose-level stock availability.

Market Gaps

Underserved Segments

Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed. who still run the workflow in spreadsheets, generic docs, email, or chat threads.
Small teams in US GLP-1 access and pricing data — a real-time index of brand-name GLP-1 (Ozempic, Wegovy, Zepbound, Mounjaro) stock, dose availability, and cash-pay price across pharmacies and manufacturer direct channels. that feel the pain weekly but are too narrow for broad incumbents.
New adopters who need guided proof before committing to a larger platform.

Feature Gaps

A narrow workflow that reaches value without configuration-heavy onboarding.
A buyer-facing proof artifact that shows time saved, risk reduced, or communication improved.
A handoff path from manual concierge service to repeatable software.

Differentiation Levers

Use specificity as the wedge: one buyer, one workflow, one measurable result.
Show proof earlier than broad competitors with before-and-after examples and small pilot data.
Keep implementation lighter than incumbent suites or generic AI assistants.

Execution Plan

Business type: Two-sided marketplace
Timeline: 8-12 weeks
Budget: Local-first MVP budget: $0-$10K before paid acquisition.
MVP approach: Build only the first-win workflow for “GLP-1 pharmacy index” and keep research, setup, and exceptions manual until the wedge is proven.
Initial offer: Concierge review or paid template

Acquisition Channels

Community pain posts: Problem teardown, interview ask, and short demo clip. Cadence: Weekly. Metric: 5 qualified calls or 10 detailed replies in 7 days
Direct outreach: Concierge pilot offer with a manually prepared sample. Cadence: Daily during validation. Metric: 3 paid pilots, LOIs, or budget-owner follow-ups
Searchable comparison content: Before-and-after page or alternatives memo for the exact workflow. Cadence: Bi-weekly. Metric: Organic clicks, booked demos, or waitlist joins from comparison intent
Launch directory: Single-purpose demo and first-win story. Cadence: Once MVP is clickable. Metric: 25% demo completion or 10 waitlist joins

Milestones

Interview 10 people who match the buyer persona.
Ship a clickable demo or concierge workflow that produces the first useful artifact.
Run one paid pilot or collect explicit pricing objections before automating the rest.
Promote to a deeper build plan only after the wedge survives validation.

Success Metrics

Problem resonance: 5+ calls or 10+ detailed replies.
Activation: 25% of demo visitors complete the first-win path.
Commercial pull: 3 paid pilots, LOIs, or concrete procurement next steps.

Framework Fit

Value equation: dream outcome 8/10, perceived likelihood 6/10, time delay 4/10, effort and sacrifice 4/10.
Market matrix: Category king candidate. High value plus high uniqueness deserves deeper research; lower uniqueness requires a clear distribution advantage.
Audience-community-product: audience 5/10, community 9/10, product 4/10.
Category: Two-sided marketplace for Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed.; likely alternative is Ro GLP-1 Supply Tracker.

Community Signals

Reddit / forums: Research lane. Look for complaints, workarounds, and repeated questions. First move: Post a problem teardown for US GLP-1 access and pricing data — a real-time index of brand-name GLP-1 (Ozempic, Wegovy, Zepbound, Mounjaro) stock, dose availability, and cash-pay price across pharmacies and manufacturer direct channels. and ask how people solve it today.
Launch communities: Validation lane. Launch traction shows whether the promise is legible. First move: Ship a narrow demo and watch which promise gets clicks.
Review and alternative pages: Objection lane. Pricing and alternatives expose buyer objections. First move: Write an alternatives page that owns one narrow use case.

Keyword Intelligence

Keyword signals should be treated as directional. The strongest terms combine US GLP-1 access and pricing data — a real-time index of brand-name GLP-1 (Ozempic, Wegovy, Zepbound, Mounjaro) stock, dose availability, and cash-pay price across pharmacies and manufacturer direct channels., the buyer workflow, and the first output the product creates.

pharmacy workflow: directional medium; rising with AI adoption; medium competition
index validation: directional low; steady niche demand; low competition

MVP Scope

MVP

Launch a free consumer ‘find-it-in-stock and cheapest cash price’ web tool for the four brand GLP-1s by drug + dose + ZIP, seeded with crowdsourced stock reports plus normalized public price data from manufacturer direct sites (LillyDirect, NovoCare), Costco/Walmart cash programs, and a GoodRx-style price layer. Layer dose-level availability alerts on top, then expose the normalized availability+price dataset as a B2B API/feed for one or two design-partner telehealth or employer-benefits buyers.

The first version should produce one trusted output, preserve source links, and make human review explicit. Everything else can stay manual: onboarding, unusual edge cases, integrations, templates, and account management.

Risks

Pharmacy stock data is not openly published — chains like CVS and Walgreens expose availability only in their own apps, so the index must rely on crowdsourced and scraped signals that can be stale, incomplete, or blocked by terms of service.
Regulatory and liability exposure: showing or routing to GLP-1 sources touches HIPAA, state pharmacy law, drug-advertising rules, and the post-shortage crackdown on compounded GLP-1s — surfacing illegitimate or compounded sources could create legal risk.
Incumbents already occupy the niche: Ro (a well-funded telehealth company) offers a free supply tracker as a funnel, and Medfinder offers a paid concierge stock-finding service, so a standalone index must out-execute on data freshness and the B2B feed.
Demand is shortage-driven and could soften further as supply fully normalizes and GLP-1 pills arrive, compressing the consumer pain point and the window for the data business.
Trying to build a broad platform before the narrow workflow has proof.

Validation Experiments

First Validation Test

Within 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments: a ‘find my dose cheapest near me’ consumer page, and a B2B page pitching the normalized availability/price API to telehealth and employer-benefits teams. Validate if at least 200 consumer stock reports are submitted in one metro and at least two B2B prospects sign a paid pilot or LOI for the feed.

Additional Tests

Write the one-sentence promise and test it in the strongest channel.
Create the lead magnet and use it to recruit interviews.
Build the smallest demo that proves the first win.

Kill Criteria

Fewer than five qualified buyers agree to discuss the workflow after targeted outreach.
No buyer can name a current cost in time, money, risk, or reputation.
The first demo does not produce a clear next step, paid pilot, or specific objection.

Founder Fit

Score: 6/10. A solo or AI-assisted founder with direct access to Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed..

Advantages

Can talk to the buyer before writing much code.
Can ship a narrow first-win demo quickly.
Can use local-first research artifacts to keep validation moving without a large team.

Gaps

Needs real buyer access, not only desk research.
Needs proof of budget or repeated urgency.
Needs a crisp wedge before broad product work starts.

Avoid If

You cannot reach the buyer directly.
The idea only sounds interesting but does not save time, money, risk, or reputation.
You want to build the full platform before validating the first workflow.

Roast

Promising enough to test, not strong enough to build broadly.

Pharmacy stock data is not openly published — chains like CVS and Walgreens expose availability only in their own apps, so the index must rely on crowdsourced and scraped signals that can be stale, incomplete, or blocked by terms of service.
A broad AI assistant can flatten differentiation unless the wedge is painfully specific.
The first release can become a generic dashboard if the job is not named tightly.

Hard Questions

Who wakes up already trying to solve this?
What do they stop paying for or stop doing when this works?
What proof would make a skeptical buyer trust it in one screen?
What is the smallest paid version of this idea?

De-Risking Moves

Sell a manual pilot before building automation.
Record five exact phrases buyers use to describe the pain.
Cut any feature that does not support the first measurable win.

Build Handoff

Build Prompt

Build a narrow MVP for “GLP-1 pharmacy index” for Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed.. Preserve the evidence, build only the first-win workflow, include source links, and treat Within 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments: a ‘find my dose cheapest near me’ consumer page, and a B2B page pitching the normalized availability/price API to telehealth and employer-benefits teams. Validate if at least 200 consumer stock reports are submitted in one metro and at least two B2B prospects sign a paid pilot or LOI for the feed. as the first acceptance gate.

Review Prompt

Review the “GLP-1 pharmacy index” MVP for over-breadth, unsupported claims, weak buyer proof, privacy risk, and missing validation instrumentation. Do not approve expansion until the kill criteria and success metrics are measurable.

Build Actions

Delete any report section that feels generic before building.
Run the lead magnet and first-win demo tests.
Promote to deeper implementation only once the wedge survives interviews or paid-pilot outreach.

Sources

GLP-1 No Longer on FDA’s Drug Shortage List - Reports that injectable tirzepatide (Mounjaro/Zepbound) came off the FDA shortage list in December 2024 and semaglutide (Ozempic/Wegovy) in February 2025, marking the shift from a national shortage to residual, localized supply issues.
Telehealth company Ro launches GLP-1 supply tracker to help patients navigate shortages - Describes Ro’s free, open-access GLP-1 Supply Tracker that combines crowdsourced patient reports with the FDA shortage list and alerts users when a needed drug and dose is found within 100 miles, demonstrating real consumer demand for dose-level availability data.
Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site - Details manufacturer cash-pay price cuts on LillyDirect for Zepbound vials and the broader self-pay GLP-1 pricing war with Novo Nordisk’s NovoCare, evidencing the wide, channel-dependent price variation a price index would normalize.
How Much of Employers’ Annual Claims Do GLP-1 Drugs Account For? - SHRM analysis showing GLP-1 drugs now represent roughly 20% of total prescription drug costs and about 10.5% of total annual employer pharmacy claims in 2025, establishing the B2B buyer’s cost pressure and willingness to pay for steering data.